Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 26986624
Shang F, et al. (2016) Cardiovascular Protective Effect of Metformin and Telmisartan: Reduction of PARP1 Activity via the AMPK-PARP1 Cascade. PLoS One 11, e0151845 26986624
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T172-p - AMPKA2 (mouse)
Modsite: sDGEFLRtsCGsPNY SwissProt Entrez-Gene
Orthologous residues
AMPKA2 (human): T172‑p, AMPKA2 (mouse): T172‑p, AMPKA2 (rat): T172‑p, AMPKA2 (pig): T172‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE AMPKA2 (human) transfection of constitutively active enzyme, pharmacological inhibitor of upstream enzyme, activation of upstream enzyme, genetic knockout/knockin of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin_2 decrease
high_glucose decrease
H2O2 decrease
metformin increase
telmisartan increase

S1176-p - eNOS (mouse)
Modsite: TSRIRtQsFsLQERQ SwissProt Entrez-Gene
Orthologous residues
eNOS (human): S1177‑p, eNOS (mouse): S1176‑p, eNOS (rat): S1176‑p, eNOS (rabbit): S1183‑p, eNOS (pig): S1179‑p, eNOS (cow): S1179‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human

S177-p - PARP1 (mouse)
Modsite: LGFRPEYsASQLKGF SwissProt Entrez-Gene
Orthologous residues
PARP1 (human): S177‑p, PARP1 (mouse): S177‑p, PARP1 iso3 (mouse): S177‑p, PARP1 (rat): S177‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE AMPKA2 (human) transfection of constitutively active enzyme, pharmacological inhibitor of upstream enzyme, activation of upstream enzyme, genetic knockout/knockin of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin_2 decrease
high_glucose decrease
H2O2 decrease
metformin increase
telmisartan increase